Hence, there are ongoing efforts to understand how the IL-3 receptor signals and to develop new therapies in AML and CML based on appropriately targeting IL3Rα. This evidence concerns the gene IL3RA and chronic myelogenous leukemia, BCR-ABL1 positive.